BRING THE PROTOCOL TO THE PATIENT

Signature

Protocol to Patient (P_2P)

NOVARTIS ONCOLOGY

Cancer Progress by Defined Health
New York, NY | March 17-18, 2015

Signature Trial Workflow



Signature

Cancer Progress by Defined Health
New York, NY | March 17-18, 2015

Slosberg E, et al. *J Clin Oncol*. 2014;32(suppl) [abstract T

Signature (P2P) Program Study Schema

N= 70-100/protocol

Solid tumors or heme malignancy pts with allowed genetic aberration

ENROLL

Enrollment

Max 2 year Follow-up from LPFT

Screening — *Baseline* — *24 mo* — *48 mo*

Primary Objective:
- Clinical benefit rate (CR+PR+SD @ 16 wks)

Secondary Objective:
- Overall Response (PR or better)
- PFS
- OS
- Safety & tolerability

Exploratory Objectives
- Pathway activation and response

Biopsy or Archival Tissue

Mutational analysis (anytime during the trial)

- Adaptive patient sparing statistics design in pre-selected patients based on genetic aberrations
- 70-100 pts /protocol (approx. 800-1000 pts total for program).
- Non competing with ongoing Novartis Sponsored trial

Signature

Cancer Progress by Defined Health
New York, NY | March 17-18, 2015

Slosberg E, et al. *J Clin Oncol*. 2014;32(suppl) [abstract TPS2646].

Site Metrics

Broad participation from many research customer categories

- 218 open sites across 8 protocols; 289 patients dosed
- 5.7 week average time to initiate a site (including academic centers) vs. 34 week industry average
- Eliminates approximately 30% non-enrolling sites (Novartis historical internal data)



(As of 15Oct2014)